Table 4.
Functional outcome at 4 and 12 months postoperatively. Values are mean (SD)
| Variable a | HFU group | Control group | (CI) | Adjusted analysisb | |
| p-value | B (CI) | ||||
| 4 months results | |||||
| SPPB | 5.5 (4.7) | 3.8 (3.4) | (0.7 to 2.6) | 0.03 | 0.9 (0.1 to 1.7) |
| CERAD | 13.3 (7.6) | 11.4 (7.5) | (0.1 to 3.7) | 0.5 | 0.5 (–0.9 to 1.9) |
| Barthel ADL | 15.7 (5.2) | 14.6 (5.5) | (–0.1 to 2.2) | 0.8 | –0.1 (–1.1 to 0.9 |
| 12 months results | |||||
| SPPB | 5.7 (4.7) | 3.6 (3.3) | (0.5 to 1.1) | 0.02 | 1.0 (0.2 to 2.0) |
| CERAD | 14.2 (8.3) | 11.5 (8.4) | (0.4 to 4.8) | 0.8 | 0.2 (–1.5 to 1.8) |
| Barthel ADL | 16.6 (4.8) | 14.3 (5.6) | (0.9 to 3.5) | 0.1 | 0.9 (–0.1 to 2.0) |
a
Short Physical Performance Battery (SPPB) scale 0–12, Consortium to Establish a Registry for Alzheimer’s disease (CERAD) scale 0–30, Barthel Activities of Daily Life (ADL) scale 0–20.
b
Linear regression on mean difference adjusted for age, gender, ASA, and pre-fracture accommodation (living in institution or home-dwelling).